Gene therapy recipients monitored for lasting effects
NCT ID NCT07081841
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 29 times
Summary
This study follows 132 people with Parkinson's disease or multiple system atrophy who previously received AB-1005 gene therapy in earlier trials. Researchers will track participants over time to see how safe the treatment remains and how long its benefits last. The goal is to better understand the long-term effects of this experimental therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University
Columbus, Ohio, 43210, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.